Nexus is a next-generation integrated ultrasonic surgical platform that combines all the features of Misonix’s existing solutions, including BoneScalpel, SonicOne and Sonastar, into a single fully integrated platform that will also serve to power future solutions. The Nexus platform is driven by a new proprietary digital algorithm that results in more power, efficiency and control. Nexus uniquely incorporates RF capabilities, allowing for use in general surgery procedures. The device also incorporates Smart Technology that allows for easier setup and use.
Physicians will be able to utilize Nexus’ increased power to improve tissue resection rates, in concert with its proprietary digital algorithm to perform more efficient bone removal procedures. In addition, Nexus’ ease of use will enable physicians to fully leverage Nexus’ impressive capabilities via its digital touchscreen display and smart system setup.
Stavros Vizirgianakis, President and Chief Executive Officer of Misonix, commented, “We are very pleased to have achieved this critical approval, marking a significant milestone for Misonix and the culmination of years of hard work.” Nexus is a powerful, highly integrated and easy-to-use system that will benefit both healthcare providers and patients by incorporating the latest advances in ultrasonic technology allowing for increased efficiency and efficacy, and thus improved outcomes. It is truly a transformational product.
“The overwhelmingly positive feedback we have received from the surgeon community since first unveiling Nexus reinforces our confidence in its potential to serve as a significant growth engine for Misonix. Nexus is a key component of our strategy to increase our presence in the neuro, spine, ortho, wound and general surgery markets. Nexus provides us with a unique opportunity to leverage our robust consignment business model, further drive the sale of consumables competitively, and extend our ability to cross-sell into multiple physician specialties. The commercialization of Nexus will expand the utilization of ultrasonic surgical applications as we continue to strategically invest in our products to become the standard of care in operating rooms and hospital outpatient departments.”
Day after day, analytical testing laboratories face considerable challenges due to backlogs of time-critical samples, rising per-sample costs, availability of skilled laboratory technicians, and chromatography maintenance and downtime. The Thermo Scientific™ VeriSpray™ PaperSpray ion source uniquely addresses these concerns. Combine the VeriSpray ion source with next-generation Thermo Scientific™ mass spectrometers to reduce time to results and cost per test with automated, high-throughput, direct mass spectrometry (MS)-based sample analysis. The VeriSpray ion source allows use of “dilute and shoot” methods to minimize solvent consumption and time-consuming sample preparation steps like derivatization, while avoiding needs for expert operators and instrument downtime. For laboratories currently performing LC or GC methods, or for those that want to add the robust sensitivity and selectivity of MS-based tests, the VeriSpray ion source provides an ideal alternative to the complexity of chromatography-based solutions.
SSO2 THERAPY FOR AMI
Current standard of care for the most severe heart attacks involves mechanically opening the blocked artery using percutaneous coronary intervention (PCI), otherwise known as angioplasty and stenting. While PCI has reduced early mortality post-heart attack over the past 25 years, significant myocardial tissue (heart muscle) death and sizable scarring may be present even after the left anterior descending (LAD) artery has been stented. This myocardial damage is linked to increased risk of heart failure and long-term mortality2.
SSO2Therapy is a novel treatment that complements PCI and is designed to minimize myocardial damage caused by acute myocardial infarction in qualifying patients suffering a LAD ST-elevation myocardial infarction (STEMI) event who are treated with primary PCI within 6 hours of symptom onset. SSO2 Therapy delivers superoxygenated arterial blood directly to at-risk myocardial tissue and is performed in the cardiac catheterization laboratory immediately after PCI is completed.
HELiOS® Personal Oxygen System for Nellcore-Puritan-Bennett®– The portable oxygen conserver is designed for the ambulatory patient in a home care environment. It is the smallest and lightest portable liquid oxygen system on the market that lasts up to 10 hours. The result was an ultra-compact package that initiated industry-wide growth in the use of liquid oxygen-based delivery devices. The award winning device is now marketed by Caire® Inc. under the names HELiOS Plus & Marathon®. We were hired to perform competitive benchmarking studies, and develop a product that incorporated their best features. Our technical input consisted of industrial design, mechanical engineering, human factors, ergonomics, and design for manufacture.
Minimed Paradigm® for MiniMed (now Medtronic) – This percutaneous insulin infusion pump is the basis for a family of wearable and water-resistant insulin pumps. It supports three basal programs and a bolus delivery option. We developed a custom, non Luer lock connector to allow for the water-resistant design. It uses a proprietary stepper motor with a captive lead screw and is powered by an easily replaceable AAA battery. We performed project management and coordination with the client’s engineering team, industrial design, graphic interface, enclosure design, electronics packaging and others. We also fabricated test fixtures for life testing motors and force sensors, and designed the occlusion sensor and thin film force sensor transducer design. We coordinated tooling, drop, immersion, and acoustic testing, and documentation transfer to production.
The NeuroThera System, De Taboada said, consists of a fiber optic cable, a handpiece, a cap that guides the laser energy to treatment locations on the scalp, accessories and a cart for portability.
When the system establishes contact with the patient’s completely shaved head, detectors in the handpiece trigger it to emit a specific wavelength of near-IR energy. “A total treatment regimen consists of treating 20 locations on the head for two minutes at each location for a total of 40 minutes of nominal treatment time,” De Taboada said.
The mitochondrial photoreceptor cytochrome C oxidase absorbs near-IR and drives adenosine triphosphate (ATP) formation by oxidative phosphorylation, he explained. The hypothesis goes that improved energy metabolism leads to mitigation of cell death in the stroke-affected tissue and to the enhancement of neuro-recovery mechanisms.
The improved neurometabolism could be beneficial not only in stroke treatment, but also in treating traumatic brain injury, and Parkinson’s and Alzheimer’s diseases, he said.
Kinterra Foot and Ankle System™ for Freedom Innovations® – The system the new state-of-the-art for adjustable prosthetic ankles, which features internal temperature fluid compensation, and a mechanism fitted with industrial-quality seals, rendering it virtually maintenance free. It offers improved stability and comfort for low to moderate impact users while walking, exercising, golfing, or hiking. We developed the overall styling (I.D.) of the ankle, and the mechanical engineering – hydraulics, pivots, shafts, valves, assembly and fixtures.
We developed an intraoral scanner for use by dentists to capture optical impressions of both the soft and hard tissues of the dental arches and digitally transfer them to an interface, lab or a computer monitor for printout and interpretation.